- Patients
- Clinical Research
- Clinical trials
- FL-020-001
Prostate Cancer
FL-020-001
A First-in-human, Phase 1 Dose Escalation and Expansion Study evaluating the Safety, Tolerability and Anti-tumor Activity of [ 225Ac]Ac-FL-020, an anti-PSMA Radioconjugate (RDC), in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)
Trial overview
Theranostics
Prostate
I
Murdoch (Oncology)
St John of God Murdoch Hospital, 100 Murdoch Drive, Murdoch, WA, 6150, Australia
(08) 9366 1500 receptiononcologymurdoch@genesiscare.comNuclear Medicine Physician
A/Prof. Joe Cardaci
MBBS, FRACP, AANNMS
Murdoch (Oncology)
Disclaimer:
This website is provided for information purposes only. Nothing on this website is intended to be used as medical advice, or to diagnose, treat, cure or prevent any disease. It should not be used as a substitute for your own health professional's advice. Any medical procedure or treatment carries risks. Before proceeding with treatment, you should discuss the risks and benefits of the treatment with an appropriately qualified health practitioner. Individual treatment outcomes and experiences will vary.